ArticleMicrobial biotechnology2021
Antifungal activity of hypocrellin compounds and their synergistic effects with antimicrobial agents against Candida albicans.
Article in Microbial biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Surface modification and nanodelivery of hypocrellin-based photosensitizers: photophysical optimization and biomedical applications.Journal of nanobiotechnology · 2026Review
- Total synthesis of a sorrentanone ester library and evaluation of its antimicrobial potential.Scientific reports · 2025Article
- Therapeutic target mapping from the genome of Kingella negevensis and biophysical inhibition assessment through PNP synthase binding with traditional medicinal compounds.Molecular diversity · 2024Article
- Anti-virulence strategy of diaryl chalcogenide compounds againstVirulence · 2023Article
- A 4-Hydroxybenzoic Acid-Mediated Signaling System Controls the Physiology and Virulence of Shigella sonnei.Microbiology spectrum · 2023Article
- Anti-virulence activity of novel (1-heteroaryloxy-2-hydroxypropyl)- phenylpiperazine derivatives against both wild-type and clinical drug-resistant Candida albicans strains.Microbial biotechnology · 2023Article
- Antifungal Activity of Amphiphilic Perylene Bisimides.Molecules (Basel, Switzerland) · 2022Article
- Inhibitory Effects and Mechanism of Action of Elsinochrome A onJournal of fungi (Basel, Switzerland) · 2022Article
- A recyclable and light-triggered nanofibrous membrane against the emerging fungal pathogen Candida auris.PLoS pathogens · 2022Article
- Anti-leishmanial compounds from microbial metabolites: a promising source.Applied microbiology and biotechnology · 2021Review
- In Vitro Antifungal Activity of Silver Nanoparticles Biosynthesized with Beech Bark Extract.Plants (Basel, Switzerland) · 2021Article
- Antibiofilm and antifungal activities of medium-chain fatty acids against Candida albicans via mimicking of the quorum-sensing molecule farnesol.Microbial biotechnology · 2021Article
- Antifungal activity of hypocrellin compounds and their synergistic effects with antimicrobial agents against Candida albicans.Microbial biotechnology · 2021Article
- Mining for novel antibiotics in the age of antimicrobial resistance.Microbial biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans is a common human fungal pathogen. The previous study revealed that quinone compounds showed antimicrobial activity against C. albicans by inhibiting cell growth. However, it was unclear whether quinones have other antifungal effects against C. albicans in addition to fungicidal effects. In this study, we assessed the inhibitory activity of a total of 25 quinone compounds against C. albicans morphological transition, which is essential for the pathogenicity of C. albicans. Several quinones exhibited strong inhibition of mycelium formation by C. albicans SC5314. Three leading compounds, namely hypocrellins A, B and C, also exhibited marked attenuation of C. albicans SC5314 virulence in both human cell lines and mouse infection models. These three compounds significantly suppressed the proliferation of C. albicans SC5314 cells in a mouse mucosal infection model. Intriguingly, hypocrellins not only attenuated the cytotoxicity of a nystatin-resistant C. albicans strain but also showed excellent synergistic effects with antifungal agents against both wild-type C. albicans SC5314 and the drug-resistant mutant strains. In addition, hypocrellins A, B and C interfered with the biological functions and virulence of various clinical Candida species, suggesting the promising potential of these compounds for development as new therapeutic agents against infections caused by Candida pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.